CVS Health (CVS, $67.35) tops Q3 earnings estimates; raises full-year guidance
CVS Health Corp. reported third quarter earnings that beat expectations. The healthcare company also boosted its full-year profit guidance.
The company’s adjusted earnings for the three months ending in September came in at $1.84 per share, higher than analyst’ estimate of $1.77 per share. The figure reflects growth of +6.35% from the same period last year.
CVS total revenues surged +36.5% year-over-year to $64.8 billion in the quarter, again exceeding analysts' expectation of $63 billion.
On a segment level, Pharmacy Services revenues rose +6.5%, on brand name drug price inflation as well as increased total pharmacy claims volume, partially offset by continued price compression and an increased generic dispensing rate – as indicated by the company. Retail sales increased +2.9%. The healthcare benefits division experienced a boost in sales from $641 million to $17.181 billion, as it included Aetna's operations to its legacy business.
For the full year, CVS has raised and narrowed its earnings guidance range to $6.97-$7.05 per share.
CVS in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 19, 2025
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where CVS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where CVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
CVS moved above its 50-day moving average on November 21, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 238 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on November 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on October 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.366) is normal, around the industry mean (4.117). CVS's P/E Ratio (206.500) is considerably higher than the industry average of (34.411). Projected Growth (PEG Ratio) (0.684) is also within normal values, averaging (1.004). CVS has a moderately high Dividend Yield (0.034) as compared to the industry average of (0.023). P/S Ratio (0.252) is also within normal values, averaging (0.634).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry PublishingBooksMagazines
Advertisement